Ductal carcinoma in situ: Molecular and cellular basis of malignancy.

Fariba Behbod; Emre Arslan; Qian Zhu; Hong Yan; Benjamin Strope; Jamie L. Wagner; Kelsey E. Larson; Timothy A. Fields; Allison Aripoli; Ashley Huppe; Onalisa Winblad; Christa Balanoff; Jessica Peterson; Molly Hill; Camron Smith; Eric C. Chang; Andrew K. Godwin; Seema A. Khan; Carol J. Fabian; Kunal Rai

doi:10.1200/jco.2024.42.16_suppl.e12582

Key Points

Invasive progression in ductal carcinoma in situ is driven by stem-like epithelial cells, which reprogram their local immune microenvironment to avoid surveillance.
Profiling of 60,000 cells revealed elevated endothelial fractions in invasive ductal carcinoma in situ, whereas plasma and T cells predominated in non-invasive lesions.
Single-cell RNA-sequencing analysis with CytoTRACE identified FOXA1 and GRHL2 as stemness drivers, though findings require validation beyond the mouse model.

Implication

Preclinical study uncovers transcriptional drivers and immune evasion in ductal carcinoma in situ, highlighting mechanisms governing invasive progression.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Behbod et al. (2024) studied this question.

synapsesocial.com/papers/68e67050b6db6435875fa766 https://doi.org/10.1200/jco.2024.42.16_suppl.e12582

View Full Paper

Ask AI

Bookmark

Share

Ductal carcinoma in situ: Molecular and cellular basis of malignancy.

Key Points

Implication

Discussion

Cite This Study

Ductal carcinoma in situ: Molecular and cellular basis of malignancy.

Key Points

Implication

Discussion

Cite This Study

Keep reading

Keep reading